Melanoma Bridge’s Presidents are glad to invite the submission of abstracts for the presentation of Oral Communications and Posters at next meeting held from December 4th to 6th, 2025
The topics are:
- Emergent Strategies
- Predicting and managing immune-related adverse events
- More Translational Research in Melanoma
- Melanoma Tumor Biology
Attendees are expected from all around the world and encouraged to submit their abstracts for poster or oral presentation during the Melanoma Bridge Congress.
Deadline for Abstracts Submission:
Submission opening: May 30th, 2025
Submission deadline: Oct 10th, 2025
Notification: Oct 30th, 2025
Guidelines for Authors: PDF
Submit your abstract as word file by e-mail to abstract@melanomabridge.org
Receipt of your abstract will be acknowledged by e-mail within a few days.
For information please contact abstract@melanomabridge.org or info@melanomabridge.org
- UNRAVELING THE PHENOTYPIC HETEROGENEITY IN MELANOMA AT SINGLE-CELL LEVEL THROUGH IMAGING-BASED SPATIAL PROTEOMICS
Roberta Turiello*, Tim Kempchen, Marieta Toma, Michael Hölzel - THE INTEGRATION OF GENOMICS AND FUNCTIONAL CHARACTERIZATION OF “OFF-THE-SHELF” CD19-CAR-T CELLS ALLOWS THE IDENTIFICATION OF MULTIPLE T CELL SUBSETS WITH EFFICIENT ANTI-TUMOR ACTIVITY AND LOW PRO-INFLAMMATORY PROFILE
Salim Bougarn, Mohammed Toufiq, Mohammed El-Anbari, Shana Jacob, Saroja Kotegar Balayya, Evonne Chin-Smith, Neha Gopinath, Alex Issam Tout, Fazulur Rehaman, Rebecca Mathew, Lisa Mathew, Kun Wang, Li Liu, Abdul Rahman Salhab, Oleksandr Soloviov, Sara Tomei, Waseem Hasan, Sahar Da’as, Damien Chaussabel, Damilola Olagunju, Deepa Subramanian, Suruchi Mohan, Chiara Bonini, Monica Casucci, Cristina Maccalli * - REAL-WORLD EFFICACY OF IMMUNOTHERAPY IN PATIENTS WITH ACRAL MELANOMA IN SPAIN: RESULTS FROM THE GEM1801 STUDY
Maria Gonzalez-Cao*, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, Almudena García Castaño, Teresa Puértolas, Enrique Espinosa, Javier Medina, Lorena Bellido, Alfonso Berrocal, Margarita Majem, Rafael López Castro, Salvador Martín Algarra, Iván Márquez-Rodas - PRIMARY EFFICACY, SAFETY, SURVIVAL, AND INITIAL BIOMARKER DATA FROM THE REGISTRATION-INTENDED COHORT OF PATIENTS WITH ANTI–PD-1–FAILED MELANOMA FROM THE IGNYTE CLINICAL TRIAL WITH RP1 COMBINED WITH NIVOLUMAB
Dirk Schadendorf*, Caroline Robert, Mohammed M Milhem, Joseph J Sacco, Judith Michels, Gino K In, Eva Muñoz-Couselo, Georgia M Beasley, Jiaxin Niu, Bartosz Chmielowski, Trisha M Wise-Draper, Tawnya Lynn Bowles, Katy K Tsai, Céleste Lebbé, Caroline Gaudy-Marqueste, Mark R Middleton, Adel Samson, Junhong Zhu, Marcus Viana, Michael K Wong - A RANDOMIZED, CONTROLLED, MULTICENTER, PHASE 3 STUDY OF VUSOLIMOGENE ODERPAREPVEC COMBINED WITH NIVOLUMAB VS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH ADVANCED MELANOMA THAT HAS PROGRESSED ON ANTI–PD-1 AND ANTI–CTLA-4 THERAPY (IGNYTE-3)
Caroline Robert, Jason J Luke, George Kong, Giuseppe Gullo, Tim Hanke* - CROSS-METHOD COMPARISON FOR BRAF V600 MUTATION CFDNA TESTING IN MELANOMA: BRAFI STUDY
Clara Mayo de las Casas*, Joan Anton Puig-Butille, Sebastian Ortiz Reina, Eloisa Jantus-Lewintre, Ana Drozdowskyj, Pablo Cerezuela, Jose Luis Manzano, Pablo Ayala de Miguel, Ana Arance Fernandez, Miguel Angel Berciano Guerrero, Almudena Garcia Castano, Teresa Puertolas, Guillermo Crespo, Maria Quindos-Varela, Juan Francisco Rodriguez-Moreno, Alfonso Berrocal, Miguel Angel Molina, Eva Muñoz-Couselo, Enrique Espinosa, Silvia Calabuig-Fariñas, Maria Gonzalez-Cao, on behalf of the Spanish Melanoma Group (GEM) - LONG-TERM FOLLOW-UP OF PATIENTS WITH ADVANCED (UNRESECTABLE/METASTATIC) MELANOMA TREATED WITH FIANLIMAB + CEMIPLIMAB: SUBGROUP ANALYSIS FROM BLINDED INDEPENDENT CENTRAL REVIEW (BICR) EFFICACY ASSESSMENT
Omid Hamid*, Amy Weise, Kyriakos P Papadopoulos, John Crown, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Kevin B Kim, Nehal J Lakhani, Melinda Yushak, Jayakumar Mani, Fang Fang, Shuquan Chen, JuAn Wang, Israel Lowy, Mark Salvati, Matthew G Fury, Karl Lewis, Meredith McKean - FIANLIMAB-BASED COMBINATION THERAPIES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: TRIALS IN PROGRESS UPDATES
Tamar Melkadze, Miranda Gogishvili, Tamta Makharadze, Ekaterine Arkania, Vladimer Kuchava, Ki Hyeong Lee, Daniel Brungs, Nana Chikhladze, Hee Kyung Ahn, Jason Porter, Sarah Goldberg, Martin Reck, Solange Peters, Ana Baramidze* - PHASE 2 PERI-OPERATIVE STUDY OF FIANLIMAB + CEMIPLIMAB + CHEMOTHERAPY VS CEMIPLIMAB + CHEMOTHERAPY IN RESECTABLE EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
Luis Paz-Ares*, Nicolas Girard, Alex Spira, Usman Chaudhry, Maria Ghattas, Siyu Li, Mark Salvati, Israel Lowy, Matthew G. Fury, Luca Paoluzzi - NEOADJUVANT AND ADJUVANT CEMIPLIMAB FOR HIGH-RISK LOCALLY ADVANCED OR RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA: INITIAL RESULTS OF A SINGLE-INSTITUTION PHASE II STUDY
Michael Lowe*, Nicki Schmitt, Keith Delman, Jennifer Gross, Monica Rizzo, Jeffery Switchenko, Emily Henkel, Doug Parker, Nabil Saba, David Lawson, Melinda Yushak - SEX DIFFERENCES IN INCIDENCE OF IMMUNE RELATED ADVERSE EVENTS BY CHECKPOINT INHIBITORS IN CANCER – RESULTS FROM THE G-DEFINER TRIAL
Johan Franzén*, Rosalba Miceli, Alexander Eustace, Hanna Eriksson - INVESTIGATING FIBROBLASTIC RETICULAR CELLS (FRCS) REMODELING WITHIN MELANOMA TUMOR-DRAINING LYMPH NODES
Apollonio B*, Bungaro C, Fucci L, Ruggeri E, Lardo D, Costa A3, De Summa S4, Traversa D4, Armenio A5, De Risi I1, De Roma I1, Strippoli S1, Guida M1 - MIR-579-3P AS A CHECKPOINT FOR ADAPTATION TO TARGET THERAPY IN MELANOMA
Domenico Liguoro*, Italia Falcone, Stefano Giuliani, Valeria Nele, Virginia Campani, Daniela Stoppoloni, Emanuele Marra, Giuseppe De Rosa, Rita Mancini, Paolo A. Ascierto, Luigi Fattore, Gennaro Ciliberto - EXPRESSION OF SAMHD1 IN BRAIN METASTASISED CUTANEOUS MELANOMA
Sofi Vikström*, Silvia Angori, Georgios Rassidakis, Nikolas Herold, Andreas Lundqvist, Daniela Mihic-Probst, Hanna Eriksson - FROM PAP TO PAPILLOMA TO PD-1: A CENTURY OF EVOLUTION OF CERVICAL CANCER CARE
Joshua Kesterson* - BIOMARKERS PREDICTING BENEFIT OF CHECKPOINT INHIBITION IN ADVANCED MERKEL CELL CARCINOMA – A SYSTEMATIC REVIEW
Hannah Björn Andtback*, Lisa Villabona - SUB-EYELID LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA: A CASE OF SUCCESSFUL SHORTCOURSE TREATMENT WITH CEMIPLIMAB
Adriana Guarino*, Giulia Venturi, Ismaela Anna Vascotto, Laura Doni, Elisabetta Gambale, Lorenzo Antonuzzo - COMPLEMENT C3 INHIBITION WITH PEGCETACOPLAN ABROGATES NEUTROPHIL SUPPRESSOR FUNCTION AND INHIBITS CIRCULATING NEUTROPHIL EXTRACELLULAR TRAPS IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER
Brahm H. Segal*, Thejaswini Giridharan, ANM Nazmul Khan, Sora Suzuki, Celia DeJohn, Suzanne Hess, Katherine Lavigne Mager, Karen McLean, Nicole Gaulin, Peter Frederick, Sarah Werner, Igor Puzanov, Martin Kolev, Pascal Deschatelets, Emese Zsiros - A PHASE II STUDY EVALUATING LOW DOSE IPILIMUMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH MELANOMA BRAIN METASTASES
Isabella C. Glitza Oliva*, Ginny Honaker, Denai Milton, Rodabe Amaria, Michael A. Davies, Adi Diab, Jennifer McQuade, Michael Wong, Sapna Patel, Hussein Tawbi, Elizabeth Burton - METHYLATION TIL PREDICTOR ASSOCIATES WITH PROGNOSIS IN PRIMARY MELANOMA
Sharon N. Edmiston*, Siyao Liu, Yi-hsuan S. Tsai, David Corcoran, Honglin Hao, Eloise A. Parrish, David W. Ollila, Paul B. Googe, Pei Fen Kuan, Ronglai Shen, Joel S. Parker, Kathleen Conway, Irene Orlow, Klaus Busam, Cecilia Lezcano, Marianne Berwick, Nancy E. Thomas - EXPLORING THE EFFECT OF SAMHD1 ON TUMOR SUPPRESSION IN CUTANEOUS MELANOMA
Silvia Angori, Sofi Vikström, Alessandra Muni, Nikolas Herold, Andreas Lundqvist, Stina Wickström, Georgios Rassidakis, Hanna Eriksson* - A MACHINE LEARNING APPROACH TO PATIENT BENEFIT BY ANALYZING IMMUNE-RELATED PROGNOSTIC MARKERS IN COLON CANCER PATIENTS RANDOMIZED TO SURGERY OR SURGERY AND ADJUVANT CHEMOTHERAPY, IN SEARCH OF PREDICTIVE SIGNATURES
Lisa Villabona*, Jacob Thurell, Hannah Björn Andtback, Peter Ragnhammar, Giuseppe V Masucci - CHRONOimmunoTOX: Does time play a role in toxicity?
Nepote A.*, Burghgraeve G., Imbimbo M., Pedrani M., Gomez A., Spataro V., Pereira Mestre R., Sangiolo D., Espeli V., Mangas de Arriba C - UPDATED SAFETY AND EFFICACY RESULTS FROM THE FIRST-IN-HUMAN STUDY OF MDNA11 (ABILITY-1), A NEXT GENERATION ‘BETA-ENHANCED NOT-ALPHA’ IL-2 SUPERKINE, SHOW SINGLE-AGENT ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMORS
Arash Yavari*, Victoria Atkinson, Philippe Bedard, Warren Brenner, Jacqueline T. Brown, Michael Chisamore, Melissa Coello, Jim Coward, Adil Daub, Seung Tae Kim, Jenny Lee, Keyun-Wook Lee, Charlotte Lemech, Kim Margolin, Matthen Mathew, Fahar Merchant, Do-Youn Oh, John Park, Zdenka Segota, Sajeve Thomas, Przemyslaw Twardowski, Minh D. To, Ira Winer, Rosemina Merchant, Lilian Siu, Hussein Tawbi, and Paolo Ascierto - INDIVIDUALIZED NEOANTIGEN THERAPY mRNA-4157 (V940) PLUS PEMBROLIZUMAB IN RESECTED MELANOMA: 3-YEAR UPDATE FROM THE mRNA-4157-P201 (KEYNOTE-942) TRIAL
Jeffrey S. Weber, Muhammad Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, Matthew H. Taylor, George Ansstas, Kevin B. Kim, Meredith McKean, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, C. Lance Cowey, Theresa M. Medina, Jennifer M. Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Elizabeth I. Buchbinder, Georgina V. Long, INT Research and Development Author Group, Robert S. Meehan
With an unrestricted grant from
PLATINUM SPONSOR
